<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561986</url>
  </required_header>
  <id_info>
    <org_study_id>2019-004302-10</org_study_id>
    <nct_id>NCT04561986</nct_id>
  </id_info>
  <brief_title>TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients</brief_title>
  <acronym>INTERCEPT</acronym>
  <official_title>A Randomized Controlled Open-label Multi-center Study to Assess the Efficacy of TCZ in Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center study is an investigator-driven randomized controlled parallel group&#xD;
      open-label clinical trial designed to evaluate the efficacy of addition of anti-IL-6 antibody&#xD;
      tocilizumab (TCZ) to the standard of care (SOC) treatment as compared to the SOC alone in&#xD;
      reducing the decline of graft function in kidney transplant recipients with chronic&#xD;
      antibody-mediated rejection (cAMR). A total of 50 recipients will be allocated to receive&#xD;
      either TCZ (n=25) added to the standard of care (SOC) or SOC alone (n=25) for a period of 24&#xD;
      months. Patients will be followed for an additional 12 months. Protocol kidney graft biopsies&#xD;
      will be performed at baseline, at 12 and 24 months. The primary outcome is the mean rate of&#xD;
      change in graft function as assessed by estimated glomerular filtration rate (eGFR) slope&#xD;
      from baseline to 24 months after start of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 11, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in eGFR at 24 months</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Comparison of eGFR decline (eGFR slope) from baseline at 24 months after start of treatment in the two arms. The eGFR will be assessed by measured creatinine values using MDRD formula in mL/min/1.73m^2. MDRD formula is based on age, sex, ethnicity, and serum creatinine (in mg/dl) and eGFR values are calculated as follows: GFR in mL/min per 1.73 m^2 = 175 x Serum Cr^1.154 x age^-0.203 x 1.212 (if patient is black) x 0.742 (if female).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Donor-specific anti-HLA antibodies (DSA)</measure>
    <time_frame>baseline and up to 36 months</time_frame>
    <description>Change in DSA from baseline based on luminex assessments every 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse and serious events related to TCZ treatment</measure>
    <time_frame>up to 25 months</time_frame>
    <description>Assessments of incidence of any side effects including infectious complications associated with TCZ therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic changes in protocol biopsy</measure>
    <time_frame>baseline and up to 24 months</time_frame>
    <description>Histologic changes at 12 and 24 months will be compared with those in the baseline biopsies. If the criteria for cAMR are no longer fulfilled in the follow-up biopsies, response to therapy is assumed. The response will be assessed as a yes/no categorical variable. In all biopsies, which still meet the required criteria for cAMR, means of individual Banff lesion scores will be compared between the baseline biopsy and the 12- and 24-months biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in proteinuria</measure>
    <time_frame>baseline and up to 36 months</time_frame>
    <description>Assessed by urine albumin creatinine ratio (UACR) at baseline and every 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function assessed by measured GFR (mGFR)</measure>
    <time_frame>baseline and up to 36 months</time_frame>
    <description>Changes from baseline in renal function as assessed by mGFR using iohexol clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function assessed by eGFR</measure>
    <time_frame>baseline and up to 36 months</time_frame>
    <description>Changes from baseline in renal function at 12 and 36 months after start of treatment, as assessed by eGFR (CKD-EPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Incidence of patient survival at 12, 24 and 36 months after start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death-censored graft survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Incidence of death-censored graft survival at 12, 24 and 36 months after start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible change in experienced transplant-specific well-being and symptom burden</measure>
    <time_frame>upto 36 months</time_frame>
    <description>Assessed using a validated self-reported questionnaires at baseline and every 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible change in experienced perceived threat of the risk of graft rejection</measure>
    <time_frame>upto 36 months</time_frame>
    <description>Assessed using a validated self-reported questionnaires at baseline and every 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible change in adherence to immunosuppressive medications</measure>
    <time_frame>upto 36 months</time_frame>
    <description>Assessed using a validated self-reported questionnaires at baseline and every 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Arm A: Standard of care (SOC) + tocilizumab (TCZ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOC, as below + TCZ (162 mg every week, subcuataneous administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: SOC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + prednisolone (not less than 5 mg/day), all oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor</description>
    <arm_group_label>Arm A: Standard of care (SOC) + tocilizumab (TCZ)</arm_group_label>
    <other_name>RoActemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject has given their written informed consent to participate in the study&#xD;
&#xD;
          2. Recipient of living donor or deceased donor kidney transplant&#xD;
&#xD;
          3. Age ≥18 years&#xD;
&#xD;
          4. At least 12 months post-transplantation at randomization&#xD;
&#xD;
          5. Biopsy-proven diagnosis of cAMR according to the Banff 2017 criteria in index biopsy&#xD;
&#xD;
          6. eGFR ≥20 ml/min/1.73 m2&#xD;
&#xD;
          7. Epstein-Barr Virus (EBV) IgG-positive&#xD;
&#xD;
          8. For female participants of childbearing potential:&#xD;
&#xD;
               -  use of adequate contraception and a negative pregnancy test&#xD;
&#xD;
          9. Subject known to have COVID-19 previously must meet all of the following conditions:&#xD;
&#xD;
               -  Asymptomatic for at least 1 month before the start of screening&#xD;
&#xD;
               -  Re-established on background immunosuppressants for at least 1 month prior to the&#xD;
                  randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to tolerate any of the SOC treatment- tacrolimus, mycophenolate acid (MPA)&#xD;
             or prednisolone&#xD;
&#xD;
          2. Recipient of multi-organ transplants&#xD;
&#xD;
          3. De novo or recurrent renal disease that, in the Investigator's opinion, could&#xD;
             adversely influence the current allograft&#xD;
&#xD;
          4. Active viral infections such as BK virus (BKV), cytomegalovirus (CMV), EBV, COVID-19,&#xD;
             hepatitis C virus (HCV) or hepatitis B virus (HBV) infections based on polymerase&#xD;
             chain reaction (PCR) testing&#xD;
&#xD;
          5. Ongoing serious infections as per Investigator's opinion&#xD;
&#xD;
          6. History of recurrent infections requiring hospitalization&#xD;
&#xD;
          7. History of tuberculosis (TB)&#xD;
&#xD;
          8. Active TB or latent TB (positive QuantiFERON-TB-Gold test, Chest X-ray)&#xD;
&#xD;
          9. Abnormal liver function tests alanine transaminase (ALT), aspartate transaminase&#xD;
             (AST), bilirubin &gt; 1.5 x upper limit of normal)&#xD;
&#xD;
         10. Other significant liver disease as per Investigator's opinion&#xD;
&#xD;
         11. Neutropenia (&lt;2 x109/L) or thrombocytopenia (&lt;100 x109/L)&#xD;
&#xD;
         12. Signs of post-transplant lymphoproliferative disorder&#xD;
&#xD;
         13. Signs of malignancy. Exceptions are basal cell carcinoma/squamous cell carcinoma or&#xD;
             non-malignant melanoma&#xD;
&#xD;
         14. History of malignancy, unless subject has been considered to have fully recovered from&#xD;
             malignancy since &gt; 2 years, without any signs of relapse&#xD;
&#xD;
         15. History of diverticulitis, inflammatory bowel disease or gastrointestinal perforation&#xD;
&#xD;
         16. Active alcohol or illicit substance abuse&#xD;
&#xD;
         17. Serious medical or psychiatric illness likely to interfere with participation in the&#xD;
             study as per Investigator's opinion&#xD;
&#xD;
         18. Mental inability, reluctance or language difficulties that result in difficulty&#xD;
             understanding the meaning of study participation&#xD;
&#xD;
         19. Woman of childbearing potential who is unwilling/unable to use an acceptable method to&#xD;
             avoid pregnancy for the entire study period and for up to 8 weeks after the last dose&#xD;
             of study drug&#xD;
&#xD;
         20. Woman with a positive pregnancy test or who is pregnant or breastfeeding&#xD;
&#xD;
         21. Current or recent (within last 3 months) participation in another clinical drug trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seema Baid-Agrawal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplant Center, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Wennberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplant Center, Karolinska University Hospital, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomas Lorant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplant Center, Uppsala University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seema Baid-Agrawal, MD</last_name>
    <phone>+4631-342 10 00</phone>
    <email>seema.baid-agrawal@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Felldin, MD, PhD</last_name>
    <phone>+4631-342 10 00</phone>
    <email>marie.felldin@surgery.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Transplant Center, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Vastra Gotaland Regioin</state>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Seema Baid-Agrawal, MD</last_name>
      <phone>031-342 10 00</phone>
      <email>seema.baid-agrawal@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Marie Felldin, MD, PhD</last_name>
      <phone>031-342 10 00</phone>
      <email>marie.felldin@surgery.gu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Jana Ekberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Mjornstedt, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Lindnér, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Felldin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lillian Streichart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Lennerling, RN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verena Bröcker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Mölne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Holgersson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenny Nyström, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinksa University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Lars Wennberg, MD, PhD</last_name>
      <phone>+46 8 5858 2554</phone>
      <email>lars.wennberg@sll.se</email>
    </contact>
    <investigator>
      <last_name>Dan-Mikael Hauzenberger, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annika Wernerson, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Tomas Lorant, MD, PhD</last_name>
      <phone>+46 18 611 7080</phone>
      <email>Tomas.Lorant@surgsci.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Bengt Felldström, MD, PhD</last_name>
      <email>bengt.fellstrom@medsci.uu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Amir Sedigh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bengt von Zur-Mühlen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vastra Gotaland Region</investigator_affiliation>
    <investigator_full_name>Seema Baid-Agrawal</investigator_full_name>
    <investigator_title>Associate Professor and Consultant Nephrologist, Transplantation Center, Sahlgrenska University Hospital</investigator_title>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <keyword>Chronic rejection</keyword>
  <keyword>Antibody-mediated rejection</keyword>
  <keyword>Graft function</keyword>
  <keyword>Donor specific antibodies (DSA)</keyword>
  <keyword>Transplant-specific well-being</keyword>
  <keyword>Adherence</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

